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Abstract 
The possibility of decreased prostacyclin (PGI2) in 
preeclampsia-eclampsia is currently being studied by sev¬ 
eral laboritories. Because of prostacyclin's various 
actions (platelet aggregation inhibition,vasodilation, stim¬ 
ulation of renin release, and possible inhibition of the hy¬ 
pertensive effects of angiotensin II), an increase in the 
peripheral activity of this chemical could explain much of 
the altered physiology of normal pregnancy. A relative de¬ 
crease in peripheral activity could tie together the various 
pathophysiological findings of preeclampsia-eclampsia. 
Therefore, plasma 6-keto PGFxa, the stable nonenzymatic 
metabolite of prostacyclin, was measured in women with pre¬ 
eclampsia, and in those women of various gestational ages 
having a normal pregnancy. The detection method, radioimmuno¬ 
assay, could not be internally validated. It appears that 
the major problem with the assay was in sample preparation. 
Plasma 6-keto PGFjO. may be elevated in normal pregnancy. 
A decrease in plasma values was seen in those with preeclamp¬ 
sia as compared to normals of the same gestational age. In 
addition, plasma 6-keto PGFjOt. was found to correlate with 
platelet count in the preeclamptic women. 
The results of this study cannot be accepted as reliable, 
but instead should be accepted as impetus for further study. 
Gas - Chromatography-Mass Spectrometry (GC-MS) of some of the 
samples could be used for verification of this worK. Platelet 
aggregation inhibition bioassay, along with confirmation by 
GC-MS, would be the best method for future study. 
If PGI2 activity and concentrations are found to truly 
be decreased, not only would tne mechansim of preeclampsia- 
eclampsia become more clear, but a more acceptable treatment 
for the disease would be suggested. 
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I. Preeclampsia-eclampsia 
A. Clinical Definitions 
Preeclampsia-eclampsia is a common disease of preg¬ 
nancy, with an incidence of about y/o of all pregnancies. 
The etiology is unknown, despite decades of intensive 
research. 
The change in definitions and classifications of hy¬ 
pertensive diseases of pregnancy reflects the realization 
that several disease processes with several etiologies are 
involved. The old term "toxemia of pregnancy" was former¬ 
ly applied to any disorder involving hypertension, protein¬ 
uria, or edema in pregnancy or the puerperium. In 1972 the 
Committee on Terminology of the American College of Obstet¬ 
ricians and Gynecologists (1) devised the following classi¬ 
fication: 
preeclampsia Hypertension with proteinuria, edema, or both 
induced by pregnancy in the twentieth week of gestation or 
later, or before the twentieth week if there is hydatidiform 
change. 
eclampsia Convulsion not caused by neurological disease 
in a woman who fulfills the criteria for preeclampsia. 
superimposed preeclampsia-eclampsia Either disorder in a 
woman with chronic hypertensive vascular disease or kidney 
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disease.(Blood pressure must rise 30 mm Hg systolic or 15 
mm Kg diastolic.) 
chronic hypertensive disease Persistent elevation of 
blood pressure before the twentieth week or beyond six weeks 
postpartum. 
gestational hypertension Hypertension developing in the last 
half of pregnancy or the first 24 hours postpartum, without 
proteinuria or edema. 
gestational edema Generalized edema that persists after 
twelve hours of bedrest, or five or more pounds of weight 
gain in one week. 
gestational proteinuria in pregnancy not induced by hyper¬ 
tension, infection, edema, or known vascular or renal dis¬ 
ease . 
hypertension Diastolic pressure of 90 mm Hg or more; or 
systolic pressure of 140 mm Hg or more; or a rise of diast¬ 
olic pressure of 15 mmHg or more; or a rise of 30 mm Hg 
systolic or more which occurs on two separate occasions at 
least six hours apart. 
proteinuria 0.3 g/l of protein in urine collected over a 
twenty four hour period. 
edema weight gain of at least 1 kilogram in one week when 
accompanied by generalized edema. 
Preeclampsia is defined as either mild or severe. It is 
severe if any of the following occur: 
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1) blood pressure greater than 160 systolic or 110 
diastolic that does not decrease with hospital¬ 
ization and bedrest. 
2) at least 5 grams proteinuria in twenty-four hours, 
or 3 - 4 quantitative. 
3) oliguria (less than 400 cc of urine per day) 
4) cerebral or visual symptoms 
5) epigastric or right upper quadrant pain. 
6) pulmonary edema or cyanosis. 
7) thrombocytopenia 
8) hepatocellular damage. 
9) fetal growth retardation. 
Seven to ten percent of all pregnancies are complicated 
by hypertension. About half of these are due to chronic 
hypertension and half due to preeclampsia. (2) Despite its 
high incidence, studies of the disease in the past have been 
hampered by the lack of precise diagnoses and definitions. 
For example, when proteinuria and hypertension have been 
present before conception, they can often disappear 
during the third trimester, only to reappear in the third 
and continue their presence after delivery.(3) Thus dif¬ 
ferentiating between preeclampsia, chronic hypertensive 
disease, and superimposed preeclampsia can often be done 
only retrospectively. 
B. Pathophysiology 
1. Vascular Changes 
Vasospasm is a basic component of preeclampsia. The 
hypertension of preeclampsia-eclampsia is due to wide¬ 
spread systemic arteriolar vasospasm (3.4,5)* which causes 
increased peripheral resistance. Although evident through- 
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out the body, it is thought to be most significant in the 
kidneys and uterus. (6) The spasm is segmental, leading to 
areas of alternating dilation and contraction and inter¬ 
mittent interruption of capillary circulation. 
The plasma volume in normal pregnancy is increased 
forty to fifty percent over normal nonpregnant levels. (7) 
This is only partially explained by the physiologic increase 
in aldosterone. In preeclampsia, the increase in plasma 
volume is less or not evident. In severe disease, the plasma 
volume may decrease as much as thirty to forty percent (8) 
despite an increase in total body water and in sodium reten¬ 
tion. The smaller intravascular volume and space makes pre¬ 
eclamptic women much less tolerant to fluid overload or blood 
loss. (9) 
Vascular sensitivity is increased in women who devel¬ 
op preeclampsia. In normal pregnancy, there is a two-fold 
increase in renin, RPA, angiotensin, and aldosterone (6,10,22, 
11) and a fifty percent increase in cardiac output (12), 
but blood pressure is decreased. This occurs because a re¬ 
fractoriness to angiotensin II's hypertensive effects devel¬ 
ops. This refractoriness 5s not related to blood volume or 
angiotensin II levels. (13) The increases in the renin- 
angiotensin-aldosterone system contribute to the physiologic 
hypervolemia while blood pressure remains low due to vascu¬ 
lar insensitivity. Gant (14) showed that an increase in 
sensitivity to the hypertensive effect of angiotensin II 
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occurs in preeclampsia, and that this change antedates the 
onset of hypertension. 
An increase in vascular sensitivity to other pressor 
hormones such as norepinephrine and vasopressin has been 
shown in preeclamptics.(15) In fact, a pressor response 
to lying supine after lying in the left lateral recumbent 
position has been shown in women who are destined to become 
hypertensive.(11) Thus it appears that there is a definite 
vascular hypersensitivity in women who will develop preeclam¬ 
psia. 
2. Endocrinological Changes 
The increase in plasma renin,angiotensin II, and aldos¬ 
terone that occurs normally in pregnancy is significantly 
blunted in preeclampsia. (6,10,11,16) Vasopressin (17), 
deoxycorticosterone (15), and progesterone (18) levels 
are not different from levels seen in normal pregnancy. 
Renin is produced in both the uterus and the juxta¬ 
glomerular apparatus of the kidney. Part of the decrease 
in renin release may be due to the inhibitory effects of 
sodium retension and hypertension on the JGA. 
Prostaglandins are known to help regulate the release 
of renin, at least in the kidney. Recent evidence (19,20) 
that one of the prostaglandins may be the final common path¬ 
way for the different signals (sodium depletion, hypoten¬ 
sion, hemorrhage, dehydration, constriction of the renal 
artery or aorta) that increase renin output. (21) The most 
likely prostaglandin is prostacyclin. It is the major 
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product of arachidonic acid metabolism in the renal arterial 
tree, and prostacyclin is known to cause renal renin release 
in vitro, (12,19,3) 
3) Uteroplacental Changes 
It is commonly thought tnat placental perfusion is 
decreased in women with preeclampsia (15) although precise 
blood flow measurment techniques are not yet available for 
use in pregnant women. The rate of dehydroisoandrosterone 
sulfate (DS) being converted into estradiol 173 by the 
placenta has been shown to reflect placental blood flow. 
(23,24) Normally, this conversion increases steadily 
throughout pregnancy. In women who later develop hyperten¬ 
sion, the conversion at first is greater than in normals, 
and then drops as hypertension develops. The excessive 
clearance levels antedating preeclampsia may correlate not 
with increased placental blood flow, but with "hyperplacen- 
tosis," an excess of functioning placenta. Preeclampsia 
occurs with higher frequency in those with hydatidiform 
mole, or in maternal diabetes, erythroblastosis fetalis, 
and multiple gestation, all conditions in which there are 
large placentas. (15) 
A definite morphological difference can be seen in the 
placental bed of women with preeclampsia. A lack of 
"physiological changes" in the uterine spiral arteries of 
preeclamptics has been shown by several investigators. (25, 
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26,27) In normal preganacy, the spiral arteries dilate 
from the distal end proximally into the myometrial segments 
figure 1).(27) 
NORMAL PRE-ECLAMPSIA 
fig. 1. Spiral arteries in normal and preeclamptic 
pregnancies. From (27) 
This is caused by migrating endovascular trophoblast cells 
replacing the reactive musculoelastic tissue that lines the 
arteries. Such tissue infiltrates in two waves; one into 
the decidua, then after a four to six week time lag,into 
the myometrail spiral arteries. In preeclamptics, the chang¬ 
es are restricted to the decidual segments. Some phenomenon 
appears to inhibit the second wave on endovascular tropho¬ 
blastic infiltration, resulting in a relatively narrowed 
deciduomyometrial junction and the continued presence of 
reactive musculoelastic cells surrounding the arteries. 
With the onset of clinical preeclampsia, another placen¬ 
tal vascular lesion occurs. Focal areas of necrosis through 
the vascular walls develops. This "acute atherosis" (25, 
26) is seen only in the small uterine vessels. Elecronmicro- 
scopic evidence shows early accumulation of lipid in the myo- 
intimal' cells, and necrosis of medial smooth muscle. This 
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later advances to lesions with numerous macrophages present 
and with fibrin deposition. (27) 
4) Disseminated Intravascular Coagulation 
During uncomplicated pregnancy, there is an increase 
in many of the factors of coagulation, such as fibrinogen, 
prothrombin, factors VIII, VII, IX, and X, soluble fibrin, 
and fibrin degradation products. (12,28,29,30) Fibrinolysin 
is slightly decreased, as is the platelet count. 
With preeclampsia, there is greater coaguability and 
a decrease in blood volume. (28) In the hypercoaguability 
of preeclampsia, changes are in the same direction as in 
normal pregnancy, but of a greater degree. This degree 
reaches the level of manifest overcompensated disseminated 
intravascular coagulation (DIC), with severe thrombocyto¬ 
penia, high fibrinogen, and disseminated intravascular ob¬ 
structions, in about 3% of preeclamptics and 9# of eclamptics. 
(28) About 15/S of all preeclamptics develop some degree of 
thrombocytopenia. 
Coagulation parameters can be used to monitor the sever¬ 
ity of the disease. Platelet count is lower and platelet 
lifespan is shorter in preeclamptics (5*1 days) as compared 
to normals (8.9 days) and nonpregnants (9.1 days). (31) 
This is due to increased platelet consumption and micro¬ 
thrombi formation, which may be responsible for peripheral 
organ damage. Platelet count, platelet serotonin levels, 
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fibrin degradation products, and Factor VIII concentrations 
have been shown to parallel the severity of preeclampsia. 
(30,32) Thus the hypercoaguability of preeclampsia appears 
to be part of a continuum between the low level chronic intra¬ 
vascular coagulation of normal pregnancy, and DIC seen in 
a subgroup of preeclamptics and eclamptics. This concept 
agrees with the commonly held idea that coagulation changes 
in preeclampsia are probably secondary to a more basic pro¬ 
cess. 
5. Renal Changes 
In normal pregnancy, glomerular filtration rate (GFR) 
and renal blood flow (RBF) are increased over nonpregnant 
values. This situation is reversed in preeclampsia. As 
the disease becomes more severe, there is a progressive 
decrease in renal function ( lowered GFR and lower clear¬ 
ances of inulin,uric acid,creatinine) along with decreased 
renal perfusion. (^»15t33) The proteinuria seen in the 
disease is a nonselective middle molecular weight proteinur¬ 
ia consistent with functional glomerular lesions. (33.3^) 
One study suggested that there might be two forms of protein¬ 
uria; one due to the vasoconstrictor effect of hypertension 
(with relatively good fetal prognosis) and one due to mem¬ 
braneous changes (with poorer fetal prognosis). (35) 
Histologic changes found in kidney biopsies and at 
autopsies are common. At the present time, there is de- 
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bate over the existence of a pathognomonic kidney lesion. 
Glomeruli are usually enlarged with dilated capillary loops, 
foamy swelling of the endothelial cells, and subendothelial 
deposits of protein, together called glomerular capillary 
endotheliosis. (15,36) The lesion has never been found in 
nonpregnant women or in men. Fibrin/fibrinogen, immunoglob¬ 
ulins (IgG and IgM) and complement deposition are less con¬ 
stant features. On rare occasions, renal cortical necrosis 
occurs secondary to spasm of the renal arteries. No mor¬ 
phologic changes in the renal arterioles have been shown. 
The presence and duration of proteinuria corresponds to 
the occurance and severity of renal lesions. (37) 
6. Hepatic Changes 
Periportal hemorrhagic necrosis was considered former¬ 
ly to be a characteristic of eclampsia. This lesion was usu¬ 
ally found in fatal cases that went to autopsy. In liver 
biopsies done on six preeclamptics and twelve eclamptics, the 
liver biopsies appeared normal. (15) Liver function tests 
are rarely abnormal in the disease; SGOT and SGPT are occa¬ 
sionally raised, and bilrubin is rarely elevated, although 
one report noted SGOT and SGPT elevations in eclamptics but not 
preeclamptics. (38) Most investigators now consider the 
pathological changes in the liver to be variable, and most 
likely to be secondary to the more basic vascular/coagula¬ 
tion abnormalities seen in the disease. 
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7. Cardiopulmonary Changes 
The heart is subjected to the hemodynamic stresses 
of decreased intravascular volume and increased peripheral 
resistance - in preeclampsia. Heart failure from circulatory 
overload (due to overly vigorous intravenous tluid administra¬ 
tion without correction of vasospasm) has occured in some 
cases. (15i39) Pulmonary edema is often found at autopsy. 
Cardiorespiratory failure, along with cerebral hemorrhage, 
account for most of the maternal deaths occurring in pre¬ 
eclampsia-eclampsia. It appears that these events are not 
part of the primary disease process, but occur from overtax¬ 
ing the cardiovascular system with severe hemodynamic stres¬ 
ses . 
Pulmonary arteriolar resistance has been measured by 
Swan-Ganz catheter in three severe preeclamptics, and was 
shown to be at or below nonpregnant levels. ( 5 ) Although 
no data is available for arteriolar resistance in normal 
pregnant women, this finding indicates that the pulmonary 
vasculature is not involved in the vasospasm seen throughout 
the systemic circulation. 
8. Cerebral Changes 
The major brain lesions found at autopsy in women who 
died from eclampsia are edema, hyperemia,thrombosis,and hem¬ 
orrhage, which varies from petichiae to gross hemorrhage. 
Cerebral bleeding is one of the major causes of death. Hem- 
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orrhagic lesions are often found in the brains of women 
who died of other causes. (15) 
Nonspecific electroencephalographic changes usually 
exist for some time after the eclamptic seizures. Coma for 
up to 3 days was reported in six of a series of fifty-two 
preeclamptics. (39) The cause of eclamptic seizures and 
their link to the pathological changes in preeclampsia 
are still unknown. Some young women may have seizures with 
a blood pressure of only 145/85, while others can withstand 
pressures of 180/120 without convulsions. 
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II. Prostaglandins and Preeclampsia-eclampsia 
A. Metabolites and Actions 
The metabolites of arachidonic acid form a group of 
very potent compounds with a variety of vasoactive and other 
effects. They are present in nearly every tissue studied to 
date. 
Precursors are stored as ^20-14. acid esters with¬ 
in cell membranes. (42) Stimuli such as hormones, antigen 
challenge, collagen, and thrombin stimulate the release of 
fatty acids (mostly archidonic acid) by a number of acyl- 
hydrolases such as phospholipase A2 and triglyceride lipase. 
Platelet release of arachidonic acid may involve several 
enzymes such as phospholipase C and diglyceride lipase. (43) 
Once arachidonic acid is released, it is quickly met¬ 
abolized by one of two different pathways. It can be con¬ 
verted by by fatty acid lipoxygenase into the hydroxyacids 
HPETE (15-hydroxy-5,8,11,13-eicosatetraenoic acid) and 
HETE (hydroxyeicosatetraenoic acid), and to the leukotrienes. 
The required enzyme for this pathway has so far only been 
found in platelets, white cells, and lung tissue. The more 
common pathway involves conversion by fatty acid cyclooxygen¬ 
ase ( also called prostaglandin endoperoxide synthetase) into 
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the 15-hydroxy prostaglandin endoperoxides PGG2 and PGH2. 
(43,44,45) PGG2 and PGH2, with half lives of about five min¬ 
utes at 37 C, are the intermediates in the synthesis of 
prostaglandins, thromboxanes, and prostacyclin, (fig. 2) 
Agents that are known to inhibit the various steps of 
arachidonic acid metabolism are shown below. (44,46) 
phospholipids 
glucocorticoids phospolipase A2, etc. 
arachidonic acid 
non-steroidal 
antiinflam- —, 
mitory agents 
(Indomethacin, >J/ 
ASA) 
fatty acid cyclooxygenase 
PGG. 
Imidazole 
dipyridamol 
cAMP 
dibutyryl cAMP-* 
Zn 
Cd 
Burimamaide 
4 PGH. 
HTT PGES PGDP PGFPd 
thromboxane 
synthetase 
Nicotine 
Hydroxy- & 
arachidonic 
acid 
HETE 
Prostacyclin 
Synthetase 
thromboxane A2 
(TXA 2)s 
v 
thromboxane B2 
(txb2) 
Prostacyclin 
(pgi2) 
6-keto PGFjO. 
Fig. 2. Arachidonic Acid Metabolism. 
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Two of the most studied products are the vasoactive chem¬ 
icals thromboxane A2 (TXA2) and prostacyclin (PGI2), which 
act as natural antagonists. TXA2 is made chiefly by the 
platelets, and is a potent vasoconstrictor and stimulator 
of platelet aggregation. Prostacyclin, made by the vascular 
endothelium and other tissues, is a potent vasodilator and 
platelet aggregation inhibitor. An extensive research ef¬ 
fort surrounding these two products is being conducted be¬ 
cause it is thought that an inbalance between these two could 
be a final common pathway in the development of essential 
hypertension and cardiovascular degeneration. 
1) Thromboxane A2 
The chemical structure of TXA2 was first described in 
1975* (47) TXA2 causes irreversible platelet aggregation 
and platelet release of ADP, serotonin, platelet factor IV, 
calcium, lysosomal enzymes, HETE (an inhibitor of prostacy¬ 
clin synthetase), a smooth muscle growth stimulating sub¬ 
stance, and more TXA2. (45) TXA2 also causes vascular 
smooth muscle contraction. 
PGH2 is converted to TXAS by thromboxane synthetase, an 
enxyme found in platelets and the microsomal fraction of 
tissue homogenates. (44) Originally called Rat Aorta Con¬ 
tracting Substance, TXA2 has a half life of 32 minutes at 
37 C and pH 7*4. It breaks down spontaneously into throm¬ 
boxane B2 (TXB2), which is a stable, inactive metabolixe. 
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(48) No other metabolites have been reported. 
Selective inhibition of TXAS synthesis would theor¬ 
etically be important for the prevention of cardiovascular 
disease. Aspirin was initially thought to selectively 
block platelet cyclooxygenase as compared to vessel wall 
cyclooxygenase. (49) It is now apparent that aspirin 
binds irreversibly to cyclooxygenase in both tissues. How¬ 
ever, circulating platelets lack the ability to synthesize 
new enzyme during its nine day life in the bloodstream. 
Endothelium is able to make new cyclooxygenase. (45) Thus 
a low dose ASA could be useful in increasing the ratio of 
prostacyclin/thromboxane. Clinical studies on aspirin's 
effectiveness are not complete. 
A more direct approach would be to specifically block 
thromboxane synthetase. Several specific compounds, such 
as imidazole, dipyridamol, cAMP, dibutyryl cAMP, and bur- 
imamide have been found to be inhibitory. (44,46) 
2) Prostacyclin 
Prostacyclin, or 9-deoxy-6,9-epoxy-5-PGF1a, was first 
discovered in 1976. Its platelet aggregation inhibiting 
action was the basis for its bioassay even before the chem¬ 
ical structure was elucidated. (50,51) Production of PGI2 
was shown to be highest in endothelial cells, (52,53) and 
it is the major product of arachidonic acid metabolism in 
the corpus luteum, human follicular tissues, uterus, kid- 
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neys, and bovine seminal vescicles. 
Prostacyclin has a half life of two to three minutes 
at 37 C and pH 7.5* It is known to break down nonenzymaticly 
into its inactive metabolite 6-keto PGFjCt. (45,51) One group 
(43,54) suggested that not only does FGI2 break down into 
several metabolites besides 6-keto PGFJ.CX, but that one cf 
its metabolites, PGElt may be the true vasodiating and plate¬ 
let aggregation inhibiting substance (fig. 3*) This is 
currently a controversial area, and supporting data for this 
opinion has not been repeated by other labs. 
PGI 
in lungs -hydroxy- 
taglandin & 
dehycrogenase 
6,15 diketo 6,15 diketo PGFjd 
13.14 dihy- (inactive) 
dro PGFid 
(inactive) 
6-keto PGSi 
(active) 
6-keto PGFxa 
(inactive) 
fig. 3* Proposed PGI2 Metabolism (43) 
Although most of the prostaglandins are thought to 
act as autocoids (locally acting hormones), it is pos¬ 
sible that PGI2 acts as a circulating hormone. The "pri¬ 
mary" prostaglandins, such as PGE2, PGF2, and PGA, are 
rapidly converted in the lungs by 15-hydroxyprostaglandin 
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dehydrogenase. However, PG[2 has been shown to pass 
through the lungs without breakdown. Venous PGI2 infusion, 
but not PGE2 infusion, causes systemic hypotension in dogs, 
indicating recirculation. (20) Prostacyclin may even be 
released from the lung endothelium.(44) 
Besides platelet aggregation inhibition and vasodila¬ 
tion, PGI2 has been shown to be involved in at least two 
regulatory mechanisms. The kallikrein-bradykinin system 
and the renin-aldosterone angiotensin system both have some 
apparent regulation by prostaglandins, most probably prost¬ 
acyclin. The kallikrein-bradykinin system's involvement with 
prostaglandins has not been completely elucidated. 
Prostacyclin or prostacyclin-like compounds are known 
to influence the renin-angiotensin-aldosterone system in at 
least three ways: 1) Frostacyclin causes release of renin 
secretion from the kidney and possibly the gravid uterus(43, 
56); 2)prostaglandins are released from the kidney by angio¬ 
tensin II; and 3) Prostaglandins have been implicated in 
regulating vascular sensitivity to the hypertensive effect 
of angiotensin II (fig. 4) (43,56,57*58) 
(S . angiotensinogen 
—> renin - f angiotensin I 
PG<=-angiotensin II-^PG 
1_4© 
&! : 71© 
- aldosterone hypertension 
fig. 4. Effects of Prostaglandins on the renin- 
aldosterone - angiotensin system. 
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Secretion of renin from the renal cortex has been shown 
to be stimulated by the direct action of PGI2. (59) Intra- 
re nal infusion of FGI2 at 10”b g/kg/ml leads to 180$ increase 
in renin secretion and a 35$ increase in renal blood flow. 
PGES and PGD2 had lesser pressor effects. (20) Prostacyclin 
infusion has been shown to increase renin activity in nor¬ 
mal men. (56) 
Prostacyclin and /or prostacyclin-like substances are 
thought to regulate angiotensin II output and its hyperten¬ 
sive effects, and so help maintain renal blood flow during 
variations in blood pressure and total blood volume. PGE 
and PGI2 output from the renal medulla increase with infusion 
of angiotensin II. (19) Prostacyclin-like material has been 
shown to be released from the kidney with infusion of angio¬ 
tensin II, leading to blunted vasoconstrictor and antidiur¬ 
etic effects. When indomethacin is given to block prost¬ 
aglandin synthesis, the vasoconstrictor and antidiuretic 
actions are no longer blunted. (6 ,62) 
Prostacyclin (and/or another prostaglandin) could then 
regulate the system as follows: Hypotension and/ or hypo¬ 
volemia signal renin release from the kidney (via prosta¬ 
cyclin. ) This leads to increased angiotensin II and aldost¬ 
erone levels, with resultant increased water and salt reten¬ 
sion, and vasoconstriction. In the kidney, angiotensin II 
triggers prostaglandin release (mostly PGE and PGI2), which 
acts locally as a vasodilator and as stimulus for further 
renin release, with perhaps slight systemic action. The 
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systemic vasoconstriction and renal vasodilation would pro¬ 
tect the renal blood supply during periods of hemodynamic 
stress. Differential output of prostaglandins may also 
effect zonal distribution of renal blood flow. (^3) 
B. Prostaglandins in Pregnancy and in Preeclampsia 
1) Prostaglandin E 
Prostaglandins have been proposed as the regulators of 
uterine blood flow for many years. (63»59»65) Prostaglandins 
of the E series (PGElfPGE2, etc.) are potent vasodilators. 
(Because most assays are unable to distinguish the various 
E prostaglandins, they will be referred to as one group- 
PGE.) PGE must exert its effects locally, because of rap¬ 
id metabolism in the lungs by 15-hydroxyprostaglandin de¬ 
hydrogenase. Up to 907<> is metabolized in one pass. These 
two characteristics (vasoconstriction and rapid breakdovm) 
make PGE an ideal substance for regulating blood flow with¬ 
in an organ. 
Autoregulation of renal blood flow by PGE and PGI2 has 
been discussed. Like the kidney, the gravid uterus is a 
major source of PGI2, PGE, and renin. These compounds could 
together regulate uterine blood flow by the same mechanism 
as in the kidney. (57>65) Several studies have shown de¬ 
creased uterine blood flow in animals given cyclooxygenase 
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inhibitors. (66,67,68) 
There have been many reports of PGE levels in peripher¬ 
al and uterine venous plasma during normal pregnancy. Re¬ 
sults varied in both absolute plasma concentrations and in 
relative changes noted throughout pregnancy. (69) Amniotic 
fluid levels of PGE have consistently been shown to increase 
throughout pregnancy, with highest levels occuring in labor. (69) 
If PGE is at least partially responsible for the uter¬ 
ine blood supply, a change in its metabolic rate or activ¬ 
ity may cause some of the abnormalities seen in preeclampsia. 
Some researchers have proposed that a decrease in PGE, with 
a relative increase in vasoconstricting PGF2a, may have a 
central role in the disease. Speroff (65) proposed the 
mechansim shown below (fig. 5)* 
degeneration V 
of 
uterine ^L 
ischemia 
placental 
prosta- 
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There are several important problems with this mech¬ 
anism. 1) PGE has been shown not to cause systemic drops 
in blood pressure even upon intravenous infusion of large 
amounts. (20) 2) There is a decrease in the renin-aldoster¬ 
one-angiotensin system found in preeclampsia that is assoc¬ 
iated with edema, not an increase. 3) The changes in the 
coagulation system are not included. This mechanism was 
proposed before the discovery of TXA2 and PGI2. 
There are few reports of PGE measurement in patients 
with preeclampsia. Demers and Gabbe (59) measured PGE by 
radioimmunoassay in the placental tissues of preeclamptics. 
They found lowered PGE and elevated PGF2a, but these lev¬ 
els did not correlate with the severity of the disease. 
Robinson et al. found that PGE was significantly decreased 
in the amnion, chorion,and decidua of women with preeclamp¬ 
sia. (70) It is doubtful that the results of these two 
studies describe PGE changes due to preeclampsia. They 
probably do not reflect prostaglandin levels prior to the 
onset of labor, because prostaglandins are known to be in¬ 
timately involved in labor.(69,70,71) 
Another group measured the ability of the placental 
vessels to synthesize PGE and PGF. (72) No significant 
difference was found between normals and preeclamptics. 
Although perhaps not central to the disease process, 
FGE may still play an important role in preventing the 
uterine ischemia thought to occur in preeclampsia-eclamp- 
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sia. The true production rate and effects of PGE in 
pregnancy and in preeclampsia remain unclear. 
2) Thromboxanes in Pregnancy and Preeclampsia 
Changes in vasoconstriction and platelet aggregation 
are known to occur in pregnancy and preeclampsia. Since 
these are the actions of thromboxane A2, it is possible 
that they could be due to a change in its synthesis and/or 
action. In any biological systems in which TXA2 or its 
antagonist, PGIS, are implicated, it would be important to 
document production or concentrations of both compounds. 
An increase in TXA2 throughout pregnancy was measured 
by thin layer chromatography, radioimmunoassay, and gas 
chromatography-mass spectrometry (GC-MS.) (73) Levels were 
shown to double between late pregnancy \28-'}6 weeks) and 
term. TXA2 (as determined by its inactive metabolite TXB2) 
remained at the same high level during the first stage of 
labor, then rose again during delivery. Mode of delivery 
did not influence TXB2 concentrations. Preterm labor had 
levels consistent with delivery but not with dates. TXB2 
levels in preeclamptic women between 28 and 36 weeks gest¬ 
ation were not different from those of normal women of the 
same gestational age, and did not correlate with platelet 
count, factor VIII, or @-thromboglobulin. (?0) 
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3) Prostacyclin in Pregnancy 
Prostacyclin may have several actions in the maintain- 
ence of the altered physiological state of normal pregnancy, 
such as maintaining vasodilation, vascular insensitivity to 
angiotensin II, increased uterine blood flow, and increased 
levels of renin, angiotensin, and aldosterone. 
Dose-dependent systemic vasodilation with resultant 
decreased blood pressure has been shown with intravenous in¬ 
fusion of PGI2. (20) 
The insensitivity to the hypertensive effects of angioten 
sin II have been linked to prostaglandins, most likely 
PGIS. Dietary deprivation of essential fatty acids in rab¬ 
bits during late pregnancy led to increased angiotensin II 
sensitivity. (75) Infusion of angiotensin II in pregnant 
monkeys or dogs in the third trimester caused increased 
prostaglandin release and increased uterine blood flow. 
Simultaneous indomethacin infusion reversed these effects 
and caused an increased pressor response. (66,68) Preg¬ 
nant sheep given indomethacin developed significantly 
increased blood pressure and decreased blood flow to the 
kidneys, uterus, and the coteledons of the placenta. (67) 
Vascular sensitivity to angiotensin II was increased in 
normal pregnant women after taking indomethacin or aspirin. 
(58) Women taking aspirin regularly during pregnancy were 
found to have lov/er birthweight babies and an increased 
rate of stillborns compared to those who did not take aspir- 
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in. (76) Thus blockage of prostaglandin synthesis is 
linked with increased angiotensin II vascular response, 
decreased uterine blood flow, and uteroplacental ischemia. 
Although PGI2 levels were not specifically measured, it is 
known that PGI2 is the major product of arachidonic acid 
metabolism in the endothelium, uterus, and kidneys.(44) 
Prostacyclin is known to be involved in the renin-an- 
giotensin-aldosterone system in at least two other ways. 
1) Prostacyclin leads to renin release. 2) Angiotensin II 
causes prostaglandin release (PGI2 and PGE) from the kidney 
and probably the pregnant uterus. 
Possible actions of prostacyclin in normal pregnancy 
might then be summarized as in figure 6. 
Several groups have measured prostacyclin, or its 
metabolite, 6-keto PGF1a, in tissues of animals having normal 
pregnancies ; 
Terragno, et al. found 6-keto PGFiO. to be the major met¬ 
abolite of arachidonic acid metabolism in vascular tissue 
from pregnant and nonpregnant cows. (77) Highest levels 
were in fetal vascular tissue. 
Hamberg et al. found 6-keto PGFiOt to be the major 
14 
product of C-aracidonic acid in isolated human umbil- 
icical arteries. (78) Human umbilical vessels and placen¬ 
tal vessels were shown to have greater PGI2 activity than 
vessels from normal adults.(79) 
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fig. 6. Possible actions of prostacyclin in pregnancy. 
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14 Homogenates of human cervix were incubated with C- 
arachidonic acid. The production of 6-keto PGFjCt (the 
major metabolite) was six times greater per net weight in 
the ripening cervix than in the nonpregnant cervix. (80) 
Plasma levels of 6-keto PGFjd have been reported to 
increase during normal pregnancy. Lewis et al. (77) 
found significantly higher 6-keto PGFjOt in women in late preg¬ 
nancy (later than 28 weeks) and in the purperium (less than 
7 days postpartum) than in those in early pregnancy (before 
twelve weeks) or nonpregnant women. Bolton et al. (81) 
measured circulating 6-keto PGFj.0. longitudinally in twelve 
women throughout pregnancy. They found plasma levels to be 
highest at 18 to 22 weeks gestation, then decreased to 
early pregnant levels by 3^ to 38 weeks. They published 
no normal value for nonpregnant women. 
One report gives contradictory findings. Ylikorkala 
et al. (82) found no difference between pregnent and non¬ 
pregnant values of plasma 6-keto F'GFiOt, and did not find 
any changes with gestational age or other clinical parameters 
All three reports of peripheral 6-keto PGFxa used radioimmuno 
assay for detection. It appears that the true changes in 
peripheral PGI2 in normal pregnancy, if anytremain unknown. 
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4) Prosxacyclin in Preeclampsia-eclampsia 
A decrease in circulating prostacyclin has been sug¬ 
gested as the major pathway for the development of preeclamp¬ 
sia by several investigators. (83»84,85) A decrease in 
PGI2 during pregnancy, either as the result of vascular 
changes in the placenta, or as a primary event, could lead 
to the following pathological changes: 
1) increased angiotensin II sensitivity 
2) decreased renin-angiotensin-aldosterone levels due 
to lower PGI2 stimulation of renin production. 
3) Decreased blood volume and edema formation due to 
hypertension and decreased aldosterone, which lowers sodium 
resorption and causes salt and water movement into the extra- 
vascular space. 
4) higher blood pressure due to both increased angioten¬ 
sin II hypertensive effects, and an inbalance in the TXA2/ 
PGI2 ratio favoring vasoconstriction. 
5) decreased renal blood flow and glomerular filtra¬ 
tion rate due to local and systemic vasoconstriction and 
lowered intravascular volume. 
These changes could be represented as in figure ?. 
This concept is similar to the "inner vicious circle" 
model desribed by Page.(86) In the presence of predisposing 
factors (genetic susceptibility,smaller uterine vessels of 
the primigravida, multiple pregnancy, hydatidiform mole, 
etc.), pregnancy overstresses the ability of the uterine 
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fig. ?. Proposed effect of decreased prostacyclin in 
preeclampsia. 
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vasculature to supply blood to the fetoplacental unit, the 
uterine blood supply being regulated by PGI2. Insufficient 
blood supply to the placenta causes increased thropho- 
blastic tissue and thrombin release, leading to increased 
intravascular coagulation, less uterine blood flow, and 
eventually the other concomitants of preeclampsia. Once 
this positive feedback loop ("inner circle") is started, 
it is difficult to stop. The process currently can only 
be stopped clinically by removal of the uteroplacental 
unit. If the decreased prostacyclin theory is correct, 
perhaps the vicious circle may be broken by administration 
of prostacyclin, rather than delivery of a pre-term infant. 
It is also possible that PGI2 deficiency could be 
important only in the most severe cases of preeclampsia - 
those fifteen percent with thrombocytopenia. At Yale- 
New Haven Hospital in 1980, most of the maternal and peri¬ 
natal morbidity and mortality were in women with thrombo¬ 
cytopenia. Increased hypercoaguability from a TXA2/PGI2 
inbalance could be the operative mechanism responsible 
for thrombi formation in diffuse organs. Excessive plate¬ 
let consumption may render a patient so thrombocytopenic 
that hemostatic mechanisms are compromised. In the hyper¬ 
tensive patient, this may predispose her to the develop¬ 
ment of intracranial hemorrhage, one of the major causes of 
death in preeclampsia-*-eclampsia. 
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Several lines of evidence suggest that a deficiency of 
prostacyclin may exist in preeclampsia; 
The rate of PGI2 production in umbilical arteries and 
placental veins at delivery has been shown to be signifi¬ 
cantly lower in preeclamptics than in controls.(83,84,85,87, 
88) A decrease was also found in other chronic uterine 
ischemic states,(intrauterine growth retardation and essen¬ 
tial hypertension.) Measurement was made with bioassay, 
radioimmunoassay, and /or gas chromatography-mass spectrom¬ 
etry. 
Amniotic fluid in five preeclamptics had significantly 
lower PGI2 than in 15 women with uncomplicated pregnancies. 
(89) Another study found lower amniotic PGI2 in severe 
preeclampsia (N-13) as compared to normal pregnancy (N-2?), 
but not in mild preeclampsia, diabetes, rhesus-immuniza¬ 
tion; or uncomplicated intrauterine growth retardation (IUGR.) 
(90) Amniotic TXB2 levels were not different among any 
of the groups. 
These results indicate a decrease occurs in utero¬ 
placental prostacyclin production. To implicate PGI2 as 
responsible for many of the systemic manifestations of pre¬ 
eclampsia, a decrease in peripheral levels must be shown. 
Two case reports have shown PGI2 levels to drop in preeclamp¬ 
sia. One longitudinal study showed a precipitous drop in 
plasma prostacyclin five weeks before the onset of clinical 
preeclampsia in a woman who had had recurrent fetal loss from 
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this disease. (91) PGI2 infusion was begun in the woman 
when the clinical symptoms of preeclampsia developed. The 
blood pressure dropped slighty, and the woman's pulse rose 
fifteen beats per minute in response to the drug. Fetal 
death occured after four days of treatment. It was thought 
by the authors that a PGI2 infusion beginning at the time 
of the drop in plasma prostacyclin might have lead to a more 
favorable outcome. 
The same group treated a 29 year old woman with infusion 
of PGI2 for recurrent preeclampsia* after blood pressure 
was unable to be controlled by conventional antihyperten¬ 
sive medicines. Although plasma 6-keto PGF1a levels were 
apparenty not measured., the patient responded to the drug 
with a dramatic decrease in diastolic pressure (from 140 
mm Hg to 80 mm Hg.) Three episodes of fetal bradicardia 
lasting one to two minutes each occured on the fourth day 
of PGI2 administration* so the fetus was delivered by cesear- 
ian section at 2?i weeks. When the infusion was moment¬ 
arily stopped for indution of anesthesia, the patient's blood 
pressure rose to 200/110 mm Hg. After the infusion was re¬ 
started, the blood pressure returned to 130/80. The infant 
has since done well. (92) 
Remuzzi et al. (93) noted a decrease in a poorly defined 
"prostacyclin stimulating factor" in late normal pregnancy, 
but saw an increase to the nonpregnant values in preeclampsia. 
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The only published study of maternal plasma 6-keto FGFaa 
in preeclampsia (94) found no differences in these levels 
in preeclamptics women (266.4 pg/ml) versus normals (26?.0 
pg/nl), or those with other complications of pregnancy 
(diabetes, twins, premature labor, bleeding, IUGR). 
However, this study is from the same group that found no 
difference in plasma 6-keto FGFAa levels in preganat women 
versus nonpregnant women. (82) There are several problems 
with the study itself. Their measurement technique (radio¬ 
immunoassay) was never verified by gas chromatography-mass 
spectrometry, or any other methods. Thus the method may be 
so nonspecific that changes in actual 6-keto PGFaa may be 
masked. A biological blank was never described (see next 
section). Participant selection was questionable. "Pre¬ 
eclamptic^" were defined as those patients with blood pres¬ 
sures over 140/90 mm Hg. No consideration was given to 
proteinuria, edema, or coagulation changes. Whether 
patients with essential hypertension or superimposed pre¬ 
eclampsia are included in the group is not specified. 
These flaws,and the fact that only one study measuring 
6-keto PGFiCt in preeclamptics has been reported to date, 
make it important to repeat the study. 
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III. Purpose of Study 
The possibility that there is decreased prostacyclin 
(PGI2) production and action in preeclampsia-eclampsia is 
currently being examined by several laboratories. Beacuse 
of prostacyclin's various actions (vasodilation, platelet 
aggregation inhibition, and possible role in the renin-angio¬ 
tensin-aldosterone system), an increase in the peripheral 
activity of this chemical could explain much of the altered 
physiology of normal pregnancy. A relative decrease in per¬ 
ipheral and local activity could theoretically tie together 
the various pathophysiological findings of preeclampsia. 
Therefore, 6-keto PGF1a, the stable nonenzymaxic met¬ 
abolite of prostacyclin, was measured in the plasma of women 
with and without preeclampsia, to determine if there were 
any changes in peripheral concentrations of the chemical in 
these conditions. 
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IV. Techniques for Prostacyclin Measurement 
There are four major techniques for prostacyclin 
measurement ( and for all prostaglandins)(42,43): 
1) Gas Chromatograhv-Mass Spectrometry (GC-MS) Sen¬ 
sitive, specific, and definitive, but also time consuming 
and requiring expensive, delicate equipment that is not 
available to all investigators. It is the standard to 
which other methods are compared. 
2) Radioimmunoassay (RIA) 6-keto PGFjO., the stable non- 
enzymatic metabolite of prostacyclin, is detected. The 
method is extremely sensitive (to the picogram range) but 
is hampered by a lack of specificity. Relatively inex¬ 
pensive and simple. 
3) Bioassay Less sensitive and less specific, it was 
the original detection method for both TXA2 and PGI2 before 
their chemical structures were known. This is the only method 
that detects prostacyclin directly, instead of its metabolite. 
Two different types of assay are used: 
superfusion bioassay - Blood is withdrawn from an animal 
by a pump, run over three isolated assay organs, and return¬ 
ed to the animal. Smooth muscle relaxation is correlated 
with prostacyclin concentration. 
platelet aggregation inhibition bioassay A biological 
sample such as citrated plasma is added to platelet-rich 
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plasma. The sample’s ability to inhibit ADP-induced 
platelet aggregation is measured spectrophotometricly. 
(95) Calibrated by CG-MS, inhibition can be used to 
measure prostacyclin activity. Assurance that PGI2 is the 
active substance is made by demonstating its stability at 
0 C and basic pH, but not at physiologic conditions. 
4) ^C-Arachidonic acid Incorporation - Chromatography 
Used to measure the ability of a tissue to produce prosta- 
14 
cyclm. C-aracidonic acid is added to a washed tissue 
sample and incubated. The radioactive products are sep¬ 
arated by chromatographic isolation and the relative amounts 
of each product are measured with a scintillation counter 
Radioimmunoassay and bioassay are the common and most 
practical methods for prostacyclin measurement. Bioassay 
has been used for a longer time, but has the disadvantages 
of lack of sensitivty, lack of specifity, and the need to 
run each sample immediately after it is obtained. RIA was 
chosen for experimental PGI2 determinations in this study 
beause of its availability, relative simplicity, low cost, 
and sensitivity. 
A. Radioimmunoassay 
The basis of RIA is competitive binding of labeled and 
unlabeled antigen to a specific antibody. Unlabeled anti¬ 
gen (the sample) is mixed with labeled (radioactive) anti- 
gan. The two are allowed to react with a limiting and con- 
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stant amount of specific antibody. As the amount of un¬ 
labeled antigen is increased, less binding of the labeled 
antigen occurs. 3ound(antigen-antibody complexes)antigen 
is commonly separated from the free antigen by adsorption 
of free antigen onto activated charcoal. The charcoal is 
then removed by centrifugation. 
The radioactivity of the antigen-antibody complexes is 
measured. A standard (dose-response) curve is made by 
assaying known amounts of the substance. The amount of 
antigen in each unknown sample is interpolated from the 
dose-response curve. (96) 
For the particular assay used in this experiment, the 
'i 
antigen was 6-keto PGF^, The labeled antigen was ^H-6-keto 
PGF1a. Radioactivity was measured by adding phosfluor- 
escence coctail that releases photons when hit by £ parti¬ 
cles from the radioactive antigen. 
The major problem with RIA is lack of specificity. 
This is caused by nonspecific binding of other substances 
by the antibody. In prostaglandin assays, this could be 
due to other prostaglandins, related chemicals (such as 
fatty acids) or to unrelated compounds. The techniques of 
sample collection and purification can greatly affect the 
amount of materials that may bind nonspecificly to the 
antibody, and so are critical to the assay. 
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2) Sample collection 
All researchers using the 6-keto PGFjCX RIA in plasma 
agree that blood samples must be collected in cold tubes 
or syringes containg anticoagulant and a cyclooxygenase in¬ 
hibitor to stop further arachidonic acid metabolism. Some 
workers use heparin (97»98,99) but others use EDTA (ethyl- 
enediaminotatraactetate) as an anticoagulant. (81,100) 
Heparin has been reported to cause falsely elevated values 
for the 6-keto PGFiO. measurement due to inhibition of anti- 
gen-antibody binding. (96,100) Indomethacin is the most 
commonly used cyclooxygenase inhibitor, but aspirin, al¬ 
though less potent, has been shown to have comparable re¬ 
sults. 
Samples are then quickly centrifuged. The plasma is 
removed and stored at -20 "C. No data is available on the 
length of time that a sample maybe stored without changing 
its binding characteristics, but most papers specify that 
samples were assayed within a month of collection. 
3) Sample Purification 
Considerable controversy exists over the need to pur¬ 
ify a plasma sample prior to RIA. 
When RIA of a new arachidonic acid metabolite is be¬ 
ing developed, purification by several steps has been 
traditionally been used to remove any other materials 
that might bind to the antibody. Purification by extrac- 
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tion to remove more polar chemicals, followed by silica 
gel column chromatography and sometimes high pressure 
liquid chromatography (HPLC),has been used. (101,102) 
HPLC has been shown to be unnecessary for use with 
the RIA of several prostanoids. (102) and was not used in 
any of the reports descibing 6-keto PGFxa in plasma. 
Silica gel column chromatography theoretically would 
improve specificity by removing most of the other prosta¬ 
glandins. However, preliminary studies done during this 
project showed that not only was 30 - 40$ of the 6-keto 
PGF^a lost during this step, but the solvents used in 
the procedure (especially benzene) contained material which 
cross-reacted with the antibody, causing falsely elevated 
measurements. This result was confirmed by Hall. (103) 
Most often, extraction is the only purification 
procedure considered necessary. Extraction is done to dis¬ 
sociate prostacyclin from,albumin, remove polar substances, 
and to concentrate the sample so that lower concentrations 
of the compound may be detected. But several groups have 
found that extraction adds more impurities to the sample. 
(96,104) Morris, Sherman, and Sheppardson (100) noted that 
when samples derived from comparable volumes of reagent 
blanks were assayed with diethyl ether, ethyl acetate, or 
chloroform, RIA measurements were greater than those of 
unextracted plasma. Mitchell (106) found that ethyl acetate 
extraction of acidified samples caused the formation of 
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"3 or 4 other compounds"- most of which reacted to the 
antibody. One group, which used ethyl acetate extraction, 
reported water and buffer blanks of 7.8pg/ml by assay. 
However, it is unclear whether these blanks were subjected 
to the extraction procedure. (97) 
Because of these difficulties with plasma purification 
techniques, several groups suggest that plasma may be direct¬ 
ly assayed. (96,100,104) This approach would require the 
development of a "biological blank." 
Samples must be in the same milieu as the standards 
to which they are compared. Extracted samples are recon¬ 
stituted in buffer. Controls and standards are in buffer. 
If samples are not extracted, the controls and standards 
must be in the same biological matrix (plasma), but this 
matrix must not contain any 6-keto FGFjO. or cross-reacting 
materials. Attempts have been made to prepare this "biol¬ 
ogical blank" without success. (96) Morris et al. (100) 
have used the plasma from subjects treated with 1800mg of 
aspirin a day for 3 days. No mention of the plasma blank's 
actual measurement by RIA was made. Hall described charcoal 
stipped plasma blanks reading 40-50 pg/ml. (103) Mitchell 
tried removing cross-reacting substances several ways; feed¬ 
ing plasma donors aspirin for several days before sampling, 
treating plasma with charcoal before use, dializing the 
plasma, and precipitating out the 6-keto PGFiii with a spec¬ 
ific antiserum. All of these techniques changed the bind- 
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ing characteristics cf the plasma used for the biological 
blank, and lead to negative values for plasma samples com¬ 
pared with standards made up in the treated charcoal. 
It appears that all of the methods of sample prep¬ 
aration have serious drawbacks that have not been over¬ 
come . 
4) Assay Verification 
It is important to validate the results of radioimmuno- 
asay by several parameters. 
1) Specificity This is determined by the cross-reacting 
compounds and by nonspecific binding to the antibody. The 
latter is difficult to determine, but may be approached by 
measuring blanks of different solvents used in the assay. 
Cross-reactivity is calculated ass 
amount of specific antigen for 50% displacement 
cross-reacting substance needed for displacement 
2) Sensitivity Three definitions are commonly used- 
i) the amount of antigen needed for a certain percentage of 
displacement of the labeled antigen (50% displacement, or 
mass for logit=0, is commonly quoted), ii) slope of the 
dose response curve, and iii) "least detectable mass"- 
mass resulting in a response two standard deviations from 
the blank's value. 

3) Precision How closely repeated measurements of the 
same sample agree. The coefficient of variation is often 
used as an index of precision. 
coeffitient 
standard devation 
of 
variation mean of samples 
*0 Accuracy How close the measured values are to the 
actual value. This can be assessed in two ways - i) meas¬ 
urement of the samples by an independent method, such as 
GC-MS. ii) Assaying known concentrations of standard and 
comparing the assay result with the known amount. 
5) Parallelism Each sample must, on dilution, yield 
a curve that is parallel to the standard curve. This test 
can be done with the test for accuracy. A known amount of 
antigen can be serially diluted, and the slope of the line 
of measured vs. known amounts calculated. 
Without these verifications, the data cannot be con¬ 
sidered reliable. Even if all the tests done within an ass 
are acceptable, the data could still be misleading. For 
example, a substance may have low cross-rectivity, but if it 
is at very high concentrations compared to the antigen, it 
would have a significant effect on the assay. Thus it is 
important each time an assay is developed for a biological 
system such as plasma, that confirmation be made by another 
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method, preferably gas chromatography-mass spectrometry. 
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V. Materials and Methods 
Plasma 6-keto PGFjO. was measured by radioimmunoassay 
in women with preeclampsia-eclampsia, and in women having 
uncomplicated pregnancies (controls). Two studies were 
done. Study I had samples from 14 preeclamptic women and 
46 controls. All samples were extracted with ethyl ace¬ 
tate. In study II, samples from five preeclamptics and 
24 controls were prepared by different methods- ethyl 
acetate exraction, solid phase extraction, and no extrac¬ 
tion. 
A. Materials 
Inaomethacin - Merk, Sharp, and Dohme Research Laboratory, 
Rahway, New Jersey 
Ethanol - 200 proof, Pharmco, Publicker Industries Co. 
Linfield, Pensylvania 
ethyl acetate - spectrophotometric grade, Mallinckrodt, 
Paris, Kentucky 40361 
methanol - spectrophotometric grade, Mallinckrodt, 
Paris Kentucky 40361 
acetic acid - Fischer Scientific, 
Fair Lawn, New Jersey 0?410 
trimethylpentane - Spectrophotometric grade, Mallinckrodt, 
Paris, Kentucky 40361 
Phosphomolybdic acid - 3*5^ in isopropanol - Brinkmann Inst. 
Westbiy , N.Y. 11590 
Hydrochloric Acid - J.T.Baker Chemical Company 
Phillipsburg,New Jersey 08865 
Sodium phosphate monobasic - Mallinckrodt, 
St. Louis, Missouri 63164 
Sodium Chloride - Fischer Scientific 
Fair Lawn, New Jersey 07410 
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Sodium Phosphate Dibasic Heptahydrate - Mallinckrodt, 
St. Louis, Missouri 63147 
Sodium Azide - Mallinckrodt, 
St. Louis, Missouri 6314? 
Gelatin - Matheson,Coleman, and Bell 
Norwood, Ohio 45212 
Picofluor scintillation solution for aqueous samples, 
Packard Instrument Co. Downers Grove, Illinois 60515 
Quantagram thin layer chromatography plates, 5*20 cm 
Quantum Industries Fairfield, New Jersey 07006 
Isocap Liqiud Scintillation Ssytem , Chicago Nuclear 
Chicago, Illinois 
Hewlet Packard 9866 minicomputer, 
Loveland, Colorado 80537 
Heparinized vacutainer tubes,10 ml - Becton-Dickinson, 
Rutherford, New Jersey 07070 
Charcoal, Norit A - Fischer Scientific Company, 
Fair Lwan, New Jersey 07410 
Dextran T70, Pharmacia, 
Uppsala, Sweden 
Water soluble silicone, Siliclad - Clay Adams 
Pasippany, Pennsylvania 07054 
Bcrosilicate glass test tubes, 12*75 - Scientific Products 
~ Fair Lawn, New Jersey 07410 
-?H-6-keto PGFid , in acetonitrile/water 9*1» New England 
_ Nuclear, Boston, Massachusetts 02118 
%-TXBa (5,6,8,9,11,12,14,15 3h-TXB2, in ethanol, New 
England Nuclear, Boston, Massacusetts 02118 
TXB2 and 6-keto FGFjCl antisera were provided by 
Dr. Harold R. Behrman, Professor,Obstetrics and Gyne¬ 
cology and Pharmacolgy, Yale University School of 
Medicine New Haven Connecticut 06520 
B. Methods 
Participant Selection All women who were admitted to the 
Yale-New Haven Hospital labor and maternity floors with the 
diagnosis of preeclampsia-eclampsia or hypertensive dis¬ 
ease of pregnancy were eligible for the study. Participants 
were selected between November 4,1981 and February 20,1982. 
Pertinent clinical data was recorded to verify the diagnosis 
of peeclampsia-eclampsia or superimposed preeclampsia. 
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Control blood samples were obtained from pregnant women of 
various gestational ages at the YNHH Women's Center. In 
both preeclamptics and controls, the participants' permis¬ 
sion was obtained according to the Human Investigation 
Committe Protocol. 
Sample Collection ten-ml blood samples were taken by veni¬ 
puncture using a tourniquet into ice-cold heparinized 
vacutainer tubes containing one microgram of indomethacin. 
The contents of each tube was gently mixed, immediately placed 
on ice, and transported to the laboratory (approx. 3 minutes.) 
Tubes were then centrifuged at 2000xg for 10 minutes at 4"C. 
Two 2 ml aliquots of plasma were then pipetted off, care 
being taken not to disturb the buffy coat. Approximately 
2000 cpm of purified ^H-6-keto PGF1a and ^H-TXB2 in C.2 ml 
of Buffer L (described below) were added to each sample 
for recovery determination. Then each sample was vortexed 
and stored at -20 C until assay. 
Purification of Tritiated Tracers For each tracer, 100iil 
of trace in ethanol or acetonitrile/water, and 100 ^1 of 
nonradiocative standard were then each evaporated under 
Ng, and resuspended in 50/1 of 2:1 chloroformsethanol. 
Standard and tracer were spotted on separate columns of 
the same silica gel thin layer (TLC) plate, and chromato¬ 
graphed in a mixture of 22:4:10 ethyl acetate:acetic acid: 
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trimethylpentane. The TLC columns were separated, and 
the column with the standard was developed by spraying 
with 3» 5f° phosphomclybdic acid and heating until the 
standard became visible. The corresponding segment of 
the column containing tracer was collected into a fiber¬ 
glass-stopped pipette, and the tracer was eluted with 
ethanol. 
Preparation of Solvents and Buffers 
Buffer L ( NaaHP04* Hs0 , 0.538 g/l; Na2HP04-7^(3 , 1. 635 
g/l; NaN^, lg/l; NaCl, 9g/l; and gelatin, lg/l) was used 
as the diluent for the recovery tracers. 
Charcoal with fines removed was prepared by vigorous¬ 
ly mixing 20 g Norit A charcoal with 200 ml distilled water 
in a graduated cyllinder, then allowing the mixture to 
settle. The fines were removed from the top of the water 
by adsorption onto paper towels. The water was decanted, 
and the charcoal dried overnight. 
Dextran Coated Charcoal was prepared by suspending 
0.5 g clarcoal with fines removed and 50 micrograms Dextran 
T-70 in 200 ml buffer L. 
Preparation of plasma controls Charcoal-treatin plasma 
should remove all prostaglandins and so allow a standard curve 
and biological blank to be made from it, but it is possible 
that this step might alter the binding characteristics of the 
plasma. Therefore, plasma standards were made up in both 
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charcoaled and uncharcoaled plasma. For charcoaled plasma, 
250 ml of human plasma was obtained from the Blood Bank. 
Charcoal with fines removed was added to make a Sc/° w:v sol¬ 
ution. The mixture was mixed at 37 C for two hours, then 
centrifuged at 2200 rpm for fifteen minutes. The supernat¬ 
ant was filtered through a buchner funnel with filter paper 
to remove any remaining charcoal. 
Using both charcoaled and uncharcoaled plasma, two 
sets of control plasma standards were made. In each, 
6-keto PGFjO. was added to an aliquot and serial dilutions 
made for final concentrations of 2000,1000,500,250,125, 
62.5*and 0 pg/ml of added antigen. 
Sample Preparation 
Two studies were done. In the first, all samples were 
prepared by liquid/liquid phase (ethyl acetate) extraction. 
The assay was run in borosilicate glass test tubes. In 
Study II, samples from each patient and all standards were 
prepared by three methods - solid phase extraction, liquid/' 
liquid phase extraction (with ethyl acetate) and using no 
extraction. Siliconized test tubes were used. 
Liouid/liquid Phase Extraction 2 ml plasma samples, 
with recovery added, were thawed and acidified to pH 3*5 
with 0.1 ml of 1.0 N hydrochloric acid. Eight ml of re¬ 
distilled ethyl acetate were added, and each sample was 
shaken by hand for five minutes. The phases were separated 
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by centrifugation at 2200 g and 4 C for 10 minutes. The 
upper phase was pipetted off and dried under in a small 
scintillation vial at room temperature. The sample res¬ 
idues were resuspended in 2.0 ml ethanol and stored at 
-70 C until assayed. 
Solid Phase Extraction C-^g silica cartriges were at¬ 
tached to disposable syringes, and activiated by passing 
2xl ml of methanol, then 3*1 ml of distilled water through 
the cartriges. Residual fluid was removed by forcing air 
through with the syringe between each addition step. The 
2 ml plasma sample with recovery trace was added to the 
cartrige and allowed to go through. Residual sample was 
removed with air. The column was washed with 2x3 nil of 
distilled water, and the prostaglandin-containing fraction 
was eluted with 2x0.5 ml of methanol. 
Siliconized test tubes were used for'the second study. 
Borosilicate glass test tubes were immersed for 5 seconds 
in a 1:100 solution of water soluble silicone, then thor¬ 
oughly rinsed first in tap water, then distilled water, 
and allowed to dry. 
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6-keto PGFid Radioimmunoassay 
The assay was performed according to the New England 
Nuclear RIA kit instructions, except that unsiliconized 
tubes were used for study I. Treatment of extracted and 
unextracted samples were slightly different. 
Procedure for extracted samples 
Standards of 1000,500,250,100,50,25,e.nd 10 pg/0.1 ml 
of kit buffer were freshly diluted just prior to assay. 
Then 0.1 ml of each standard was aliquoted in triplicate 
into assay tubes. One ml of each extracted unknown sample 
and plasma standard was aliquoted into an assay tube and 
dried down under air at room temperature. 0.2 ml (or ten 
percent) of each sample was stored in a scintillation vial 
for later estimation of recovery. Total count (s), zero 
added mass (0) and blank (Oab) tubes were prepared. Re¬ 
agents were added to the tubes as follows: 
buffer tracer antibody 
s 900yJL 100^y 
OAb 400 100 - 
0 300 100 100 
Standards 200 100 100 
Flasma controls 300 100 100 
Samples 300 100 100 
Thus all tubes except s had a final total volume of 500 
microliters. The tubes were vortexed for 5 seconds each 
and allowed to incubate for 16 hours at 4 C. 
After incubation, all tubes were placed in an ice 
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bath for ten minutes. 500 microliters of iced charcoal 
suspension were added to each tube excepts within one min¬ 
ute. All tubes remained in the ice bath for an additional 
fifteen minutes, and then was centrifuged at 1000 g at 4 C 
for 10 minutes. The supernatant fraction was decanted into 
scintillation vials using consistent technique. 3«5 ml of 
Pico-Fluor scintillation cocktail was added, and the mixture 
was vortexed for 2-4 seconds. The samples were then 
put in the scintillation counter for radioactivity measure¬ 
ment. 
Procedure for Unextracted Samples 
Because the unextracted samples were in plasma rather 
than buffer, standards could not be in buffer. There¬ 
fore, all standrds were freshly made up in charcoaled 
plasma. 0.6 ml of each unknown sample and each plasma 
control were aliquoted into an assay tube. s, OAb, and 0 
tubes were prepared. Reagents were added to the tubes as 
follows: 
buffer tracer antibody 
s 1200,*'? 100 ^ — 
OAb 700 100 - 
0 600 100 100 
Standards 500 100 100 
Plasma Controls - 100 100 
Samples * 100 100 
Thus all tubes excet s had a final volume of 800 microli- 
ers. The rest of the procedure was unchanged. 
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C. Calculation of Results 
All calculations were made using the Hewlett Packard 
9380 minicomputer and a previously prepared program. (107) 
The standard curve was obtained from the standards in 
buffer using weighted linear regression analysis and the 
logit/ln transformation of Rodbard. (108) 
A scatchard plot of bound/free vs. bound, or 
—57^- 
logit-log() vs. In (dose of standard in pg) 
was automatically printed. The weighted linear regres¬ 
sion line was calculated between the lowest linear dose and 
the dose just producing over logit-0 displacement (or 50$ 
disp]acement of th tracer). The slope of this line affin¬ 
ity. 
The transformation yields a straight line defined by 
the equation; 
ln(dose)* (affinity)* log( —) - ln(mass for logit=0) 
c/o Recovery was calculated from C (the cpm of the 10$ al¬ 
iquot of the sample *10) as: 
Cf 
recovery - ^-04-al Cpm added for recovery determination 
Calculation of Unknowns was determined from the standard 
curve transformation by the computer program, which auto¬ 
matically corrected for the mass and added counts of the 
recovery tracer,. Total corrected count, corrected B0, and 
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corrected logit were calculated as follows: 
corrected total - s - C F 
corrected Bq - ((total count)/s)*B 
corrected OAb :(blank)- ((OAb-background)*corrected total 
- background 
B - cpm in assay tube 
corrected logit - In 
- corrected OAb 
(B/corrected B^) 
(1-b/corrected B0) 
where s - counts per minute (cpm) of the s tubes 
C - cpm in recovery vail * 10 
F - decimal fraction of the sample aliquoted into the 
assay tube 
B - cpm in the zero added mass (0) tube, corrected for 
Oab 
OAb - cpm in the zero antibody (OAb) tubes 
All values are in counts per minute (cpm) and corrected for 
background (cpm measured when empty vail is counted). 
From the corrected logit, the total mass was deter¬ 
mined by interpolation of the logit/ln transformation. 
Correction for systemic error due to mass added with recov¬ 
ery tracer v;as computed as follows; 
corrected mass - measured mass - 1COf“ 
where CE - counting efficiency of the scintillation counter,, 
The specific activity of the tracer is in dpm/pg. 
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Statistical Analysis The statistical significance of the 
difference in plasma 6-keto PGFaa between two clinically 
defined groups was found by the Student's t test: 
sd = l(xa2) - 2(x,2) - Nxs - Nx, ( _L - (N, t - 2) 1 N, N J 
t - x, - x. 
where S 
d- 
x 
dx is the standard error of the difference of the 
means, Nx - the number of data points for group 1, N8 = the 
number of data points for group 2, and xx and x2 are the val¬ 
ues of 6-keto PGFxa for gropus 1 and 2, respectively. 
For testing ths significance of the pearson product- 
moment correlation between two variables x and y, the fol¬ 
lowing equations were used: 
r - ex 
y 
=> N2XY-N2X2Y _ 
= - U XT8)'* ^N2Y2-(2Y)2)'/i 
t - rJN-2 
(1 - r*)l 
where r - correlation coefficient, 
N - the number of paired data points 
m - the slope of the correlation line 
CT' - the standard deviation of the x values 
A 
cr s the standard deviation of the y values 
vf 
The statistical significance of t for degrees of freedom(N-2) 
was found in a standard statistics text. (109) 
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VI. RESULTS 
A. Assay Parameters for Study I. 
Study I. All samples prepared by ethyl acetate ex¬ 
traction. 
/BQ (Binding with no unlabeled antigen) - 42.2/ 
2 
Correlation of logit vs. In dose r - 0.985 
Specificity Cross-reactivity of some related compounds 
(data from New England Nuclear Corporation): 
6-keto PGFj^oc 100/ 
PGF2cx 2.7'/* 
pge2 2.0 / 
txb2 0.1 / 
PGA2 0.1/ 
PGAa 0.3# 
Nonspecific binding of assay solvents and blanks 
Substance "6-keto PGF,a" 
ethanol 2 ml 12.0 pg/ml 
ethyl acetate 8 ml 10.4 
HC1 0.1 ml 1.6 
distilled water 0
 1 ro • 
distilled water 
(extracted) 
84-97.8 
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Sensitivity - Study I. 
1) Mass for logit-0 (mass needed to displace fOfo of the 
labeled antibody - 199•6 pg 
2) "Least detectable mass" (mass resulting in a response 
2 standard deviations away from the response to a zero 
dose) - 110.4 pg 
Precision and Accuracy 
Serial dilution of standards (extracted): 
Amount of 
6-keto PGFjCL 
added to 
solvent 
pooled 
plasma 
as solvent 
distilled 
water 
as solvent 
0 pg/ml 65 pg/ml 97.8 pg/ml 
0 73 84 
0 62 
62.5 93 - 
125 74 176 
250 - 276 
500 70 457 
1000 93 529 
2000 151 1198 
r2 - 0.814 r2 - 0.963 
y-intercept - 68 y-intercept - 89 
Kit Controls (specially treated plasma with either 
0 or 1000 pg/ml): 
extracted 
0 pg/ml 284 pg/ml 
unextracted 
1000 pg/ml 1223 

Study I. 
Serial dilutions of standards (unextracted) 
Amount of 
6-keto PGFjd 
added to 
pooled plasma 
measured 
6-keto FGFxa in 
pooled plasma 
solution 
0 pg/ml 58 pg/ml 
0 74 
0 66 
62.5 105 
125 139 
250 198 
500 
1000 
286 
663 
r2 - 0.9623 
y-intercept - 89 
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B. Plasma 6-keto PGF^ Values - Study I. 
gestational platelet plasma 
patient # age age count 6-keto PGF,a 
Preeclamptics-eclampticsC* - severe): 
**001 30 42 weeks 80,000 137 pg/ml 
002 20 40 190,000 67 
**003 21 32 75,000 72 
*004 25 32 170,000 160 
*005 31 40 250,000 154 
**006 26 28 370,000 220 
*007 28 38 210,000 134 
**003 21 35 130,000 - 
009 32 40 220,000 - 
*010 30 42 150,000 160 
Oil 27 41 290,000 197 
***012 26 39 290,000 274 
**013 34 3^ 130,000 89 
014 19 38 - . 126 
mean - 149 
S.D. - 61 
Controls(normal patients): 
npOl 34 8 - 231 
np02 27 34 - 246 
np03 25 1C - 130 
np04 24 - - 152 
np05 22 42 - 129 
np06 19 27 - 146 
npOS 25 38 - 171 
nplO 19 41 - 125 
npll 19 37 - 149 
npl2 30 37 - 157 
npl3 22 8 - 101 
npl4 21 38 - 114 
npl6 30 34 - 91 
nP17 19 8 - 137 
npl8 23 34 - 183 
npl9 29 8 - 102 
np20 16 - - 116 
np21 28 36 - 52 
np22 20 36 - 152 
np23 - - - 116 
np24 20 39 - - 
np25 33 12 - 134 
np26 20 - - 146 
np27 21 22 - 171 
np28 21 9 - 131 
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Plasma 6-keto PGF^ Values (continued) 
gestational platelet plasma 
patient # age age count 6-keto PGF,a 
np29 20 174 
np30 21 10 - 117 
np31 38 36 - 212 
np32 23 36 - 237 
np33 22 30 - 148 
np34 19 21 - 164 
np35 26 24 - - 
np36 25 32 - - 
nP37 31 - - - 
np38 19 35 - - 
np39 30 35 - - 
np4o 19 37 - 217 
np4l**** 19 32 - 193 
np42 18 37 - 223 
np43 21 36 - 280 
np44 41 36 - - 
np45 19 36 - 348 
np46 19 22 
**** _ twin gestation 
*** _ eclampsia 
** - severe preeclampsia 
* - chronic hypertension 
161 
mean - 163 
S.D. - 58 
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Study II. 
A. Assay Parameters 
c/oE>o (Binding with no antigen) - 41.6/6 
Correlation of logit vs. In (dose) r2 - 0.961 
Specificity Cross-reactivity is the same as in study I. 
Nonspecific binding of blanks: 
liquid- solid 
liquid phase without 
extraction extraction extracti 
stripped 64 * * 
plasma * - 196 
* 
- 218 
distilled 450 27 * 
water 91 * * 
2£i 
Sensitivity 
1) Mass for logit - 0 (mass needed to displace 50/6 of 
the labeled antibody) - 154.8 pg 
2) "Least detectable mass" (mass resulting in a re¬ 
sponse two standard deviations from the response 
to a zero dose) - for liquid/liquid extraction, 
211 - 2* 292 - 795 pg 
Not determinable for SPE or nonextracted blanks. 
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Study II. 
Precision and Accuracy 
Measured and actual amounts of 6-keto PGFjd in serial 
solutions of plasma and water were compared: 
Amount of Measured values in samples treated by: 
6-keto PGFjd ethyl solid 
added to acetate phase no 
solvent extraction extraction extraction 
solvent- charcoal' -stripped plasma 
0 pg/ml * * 
0 * 196 
0 64 * 219 
62 * * 283 
62 * * 255 
125 * * 237 
250 * * 270 
500 * * 345 
1000 55 - 339 
2000 - 95 66 
2000 - 4 394 
rs - 0.205 
y-intercept - 
slope-0.64 
solvent - distilled water 
0 450 27 
0 91 295 * 
0 94 - * 
62 95 80 159 
62 120 - 150 
125 * 50 127 
250 15 161 490 
500 254 161 490 
1000 256 244 699 
2000 359 175 1159 
2000 - - 3319 
r2 - 0.239 r2 - 0.235 r2 - 0.738 
y-intercept y-intercept y-intercept 
- 127 - 106 - -20 
slope-0.11 slope-0.06 slope -1.08 
negative value 
no data available 
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Study II. 
Plasma 6- keto PGFiO. values • 6-keto PGFjd in: 
patient age 
gestational 
age 
platelet 
count 
ethyl 
acetate SPE none 
controls s 
50 35 9 weeks - 55 - 117 
51 19 25 230,000 301 - - 
52 18 - - 102 - - 
53 19 16 - 116 22 53 
54 26 18 - 151 - 48 
55** 20 36 220,000 180 38 43 
56 23 - - 92 30 63 
57 20 - - 122 - 166 
58 24 - - 89 - * 
59 23 16 190,000 93 * 67 
60 18 35 200,000 56 * 73 
61 22 33 180,000 364 * * 
62 24 36 180,000 101 28 ■«- 
63 24 - - 140 - - 
65 26 18 210,000 89 - - 
66 23 8 240,000 97 23 91 
67 19 23 220,000 111 - 61 
68 25 - - 176 - 45 
69 26 34 260,000 133 27 40 
70 19 37 190,000 100 * # 
71 19 16 360,000 103 * 93 
72 23 34 190,000 37 27 * 
73 22 32 190,000 - 23 50 
74 19 - - 129 - * 
mean 130 27 72 
S.D. 76 5 34 
** twin gestation 
* uninterpretable (negative) values 
- no data available 
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Study II. 
Plasma 6-keto PGFiO. values: 
gestational 
patient age age_ 
preeclamptics: 
64 17 29 
016 19 33 
017 18 28 
018 25 39 
019 32 31 
longitudinal study of a pre 
015 33 31 1/24 
1/26 
1/27 
1/28 
1/29 
1/30 
1/31 
2/1 
2/4 
2/11 
platelet 
count 
6-keto 
ethyl 
acetate 
PGFj. 
SPE 
a in: 
none 
60,000 * * * 
200,000 
- 19 45 
65,000 61 * * 
150,000 72 - * 
110,000 
_ 
- - 
mean - 
clamptic: 
75 S. D. - 16 
140,000 129 ~ 66 
180,000 124 45 72 
210,000 - 10 * 
250,000 124 * 21 
250,000 * * 90 
240,000 129 * 38 
240,000 130 37 53 
250,000 113 * * 
- 105 27 41 
_ 130 * * 
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C. Correlation of 6-keto PGFAa with Clinical Findings 
In study I, the correlation between 6-keto PGF1a and 
platelet count in preeclamptics (r=0.73) was found to be 
statistically significant, as was the correlation between 
6-keto PGFid and gestational age in the controls (r^O.285, 
p 0.05) The difference in 6-keto PGFAa in preeclamptics 
(N—9) and controls (N=15) in the twenty seventh week of 
gestation and beyond was not stasticically significant. 
The correlation of 6-keto PGFxa and systolic blood 
pressure, diastolic pressure, maternal weight, infant 
weight, and maternal age was not significant. 6-keto 
PGFAa levels were not different between primiparas and 
multiparas in the control group. All preeclamptic 
women were primiparas except one with a history of preeclamp¬ 
sia in previous pregnancies. 
1) 6-keto PGFtO: vs, platelet count in preeclamptics 
r - 0. 7333 N - 11 t- 3.235 0.05?p>0.01 
2) 6-keto PGFjCi vs. Gestational age .in contro-ls 
r = 0.285 N - 31 t - 2.118 0.05>p>0.01 
3) 6-keto PGF-,a vs. gestational age in preeclamptics 
r = 0.189 N - 12 t - 0.751 N.S. 
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3) 6-keto PGF-,0. vs. systolic blood pressure in controls 
r —0.319 N = 30 t - 1. 783 N.S. 
4) 6-keto PGF,g vs. diastolic blood pressure in controls 
r --0.11889 N - 37 t = 0.749 N.S. 
4) 6-keto PGFid vs. maternal weight in controls 
r - 0.859 N -=■ 24 t = O.787 N.S. 
5) 6-keto PGF-,0. vs. infant birth weight in all 
r - 0.277 N - 17 t - 1.074 N.S. 
6) 6-keto PGF-,0 vs. maternal age in controls 
r = 0.049 N - 35 t - 0.282 N.S. 
7) 6-keto PGF-,0 in primiparous vs. multiparous controls 
nulliparae N = 12 multiparas N = 18 
x * 165 pg/ml x - 155 pg/ml 
SD - 23.96 t = 0.004 N.S. 
x 
8) 6-keto PGF-,o in preeclamptics vs. controls 
preeclamptics N ■= 9 controls N = 15 
x - 149 pg/ml x = 191 pg/ml 
S.D.- 70 pg/ml S.D.- 73 pg/ml 
SD * 35.31 t = 1.169 N.S. 
x 
N.S. - not statistically significant 
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fig. 3, 6-keto PGFxa vs. platelet count in preeclamptic 
o 
fig. 9. 6-keto PGFxa vs. gestational age in controls 
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VII. Discussion 
1) Validity of Data 
The data from the two studies must be considered 
unreliable because of the inability to show appropriate 
results with the measurements of the serial dilutions of 
standards. 
In study I, the extraction procedure appeared to in¬ 
troduce antibody-reactive material. Significant 6-keto- 
PGFid was measured in distilled water blanks that were 
assayed after extraction (90 pg/ml) as compared to water 
blanks that were assayed without extraction. (0-2 pg/ml) 
The solvents used in the extraction were each tested indi¬ 
vidually, and the low measured values could not totally 
account for the high water blank. 
The results of measurements of serial dilutions of 
known amounts of 6-keto PGFxa in both pooled plasma and 
distilled water were done to assess the accuracy and par¬ 
allelism of the system. The standards added to water 
which were then extracted showed fairly good correlation 
between measured and actual values, despite a high blank 
(90 pg/ml.) The standards in pooled plasma that had been 
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extracted with ethyl acetate showed poor correlation with 
actual values. Throughout the dilution range (0-2000 pg/ml), 
the measured values were fairly constant (65-151 pg/ml). 
This could be due to several factors: i) The extraction may 
have broken down added 6-keto PGFjd into antigenicly unreact¬ 
ive components, or ii) the ethyl acetate may not extract all 
of the unphysiologically high amounts of the 6-keto PGF1a 
from the aqueous phase of the plasma. 
All samples in Study I were extracted with ethyl ac¬ 
etate. In view of the poor results fron extracted standards in 
plasma, the data from Study I cannot be considered reliable. 
As part of Study I, a set of plasma standards which had 
not been extracted was assayed. The correlation between 
measured and actual concentrations was much better (r2- 0.98, 
slope - 0.57) than the correlations of the extracted plasma 
samples (r2- 0.81, slope - 0.03). Because of the high 
blanks and poor results in the plasma that had been extract¬ 
ed compared to those without extraction, it became clear 
that the extraction process itself caused a significant 
lack of precision and accuracy. 
Thus to determine which method of preparation leads 
to the most precise and accurate results, Study II was done. 
Each control, and most samples in this study, were pre¬ 
pared in three different ways - ethyl acetate extraction 
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(liquid/liquid phase), solid phase extraction (SPE), and 
no extraction. 
Blank values in the second study varied greatly, from 
negative values to 450 pg/ml. Correlations between measured 
and actual values of standard dilutions for both ethyl acetate 
extraction and no extraction were much worse than the same 
experiments done in Study I. Correlations for standards 
treated with solid phase extraction were equally poor. For 
all three methods, many of the results were uninterpretable 
because the radioactivity of the bound antigen in the sample 
were higher than that of the zero tubes (those with no 
added sample.) This means that negative values for 6-keto- 
PGFjd were obtained. 
It is apparent that the assay itself did not work 
appropriately in Study II. The standard curve in buffer, 
used to determine the dose-response curve, was not acceptable, 
as shown below. 
CM 
-P O 
•H 
W) O 
f—I CM 
I 
I. 
Study I. 
3 4 5 6 
ln(dose) 
CM 
23° 
W> O 
rH 
CM 
I 
Study II. 
'2 3 ~4 5 6" 
ln(dose) 
fig. 10. Dose-response curves for Studies I and II 
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This failure of the assay in Study II could be due to 
several factors: 
i) Error in experimental technique. Although conditions 
for the assay ( treatment of reagents, pipetting technique, 
equipment, incubation period, and charcoaling technique) 
were kept as constant as possible, errors in performing the 
assay could not be ruled out. 
ii) Siliconized test tubes. In study I, the test tubes 
for the assay were unsiliconized borosilicate glass. Test 
tubes for Study II were siliconized according to the NEN assay 
kit instructions. This was to decrease the amount of 6-keto 
PGFja that adsorbed to the glass. The siliconizing agent 
or the method used may have altered the assay. 
iii) Reagent Instability. Reagents had been refriger¬ 
ated at 4"'C for an additional month for Study II. Although 
lyophylized reagents were not reconstituted until the evening 
that the assay was performed, it is possible that the reagents 
may have been unstable. The charcoal was supplied as a sus¬ 
pension in phosphate buffer, and was reported to be stable for 
two months. There was a six week period between obtaining 
the suspension and running the assay for Study II. 
It was hoped that Study II could suggest which method of 
sample preparation led to the most accurate results, and would 
also provide more data on 6-keto PGF^a. in the plasma of nor¬ 
mal and preeclamptic women. However, with the study itself 
being unreliable, conclusions cannot be drawn from this study. 
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2) Correlation of 6-keto PGFiO. with Clinical Results 
It is tempting to accept the data on plasma 6-keto PGFjOc 
obtained from Study I, despite the problems with verifying 
the assay's validity. Although there was poor correlation 
between measured and actual values in plasma samples spiked 
with various amounts of synthetic 6-keto PGR^, the correl¬ 
ation is fairly good for water spiked with 6-keto PGFiii. 
More interestingly, the values found in plasma agree with 
previously reported results. Mean levels of 6-keto PGF,a were 
low in early pregnancy (135 pg/ml), increased in mid preg¬ 
nancy (158 pg/ml), and further increased in late pregnancy 
with greatly increased scatter (215 pg/ml), as seen in fig¬ 
ure 8. This is statistically significant, and similar to the 
patterns found by Lewis et al. (77) and Bolton et al. (81). 
6-keto PGFid was found to be lower in preeclamptics 
(149 pg/ml) as compared to normal women during the twenty- 
seventh week of gestation or later (191 pg/ml), but this 
difference was not statistically significant. If the assay 
was valid, this data would significant to help support the 
theory that decreased peripheral levels of PGI2 might be an 
operant mechanism in preeclampsia-eclampsia. 
Another finding was the s tat is ic_al.ly significant (p 0.05) 
correlation of 6-keto PGFjOi with platelet count in women 
with preeclampsia. This could be expained two ways: 
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i) A decrease in prostacyclin in vivo caused an inbal¬ 
ance in the PGI2/TXA2 ratio, leading to increased intravas¬ 
cular coagulation and platelet consumption, and therefore 
lowered platelet count. 
ii) A cross-reacting substance was released from the 
platelets upon sample collection. 
It is difficult to distinguish between these possibilities 
without verification by GC-MS. 
The results of this study offers some data that would 
be tempting to accept as evidence that peripheral 6-keto 
PGFj.cc , and therefore, PGI2, is increased in normal preg¬ 
nancy and decreased in women with preeclampsia. This can¬ 
not be accepted with enthusiasm beause assay parameters were 
not shown to be valid. GC-IVE measurement of a subset of the 
samples nay show whether 6-keto PGFjOc measured by RIA was 
preoportional to the 6-keto PGFiOC in the sample. Such evi¬ 
dence would make the findings of this study significant in 
the study of peripheral PGI2 in preeclampsia. 
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VIII. Summary 
Prostacyclin production and activity in preeclampsia- 
eclampsia is currenly under investigation at several labor¬ 
atories. Because of prostacyclin's various effects (plate¬ 
let aggregation inhibition, vasodilation, stimulation of 
renin release, and possible regulator of the hypertensive 
effects of angiotensin II), an increase in the peripheral 
activity of this chemical would explain much of the altered 
physiology of normal pregnancy. A relative decrease in per¬ 
ipheral and local action could theoretically tie together 
the many pathophysiological findings of preeclampsia-eclamp¬ 
sia. 
Therefore, plasma 6-keto PGFiCi, the stable nonenzymatic 
metabolite of prostacyclin, was measured in women with pre- 
eclampsia and in those of various gestational ages having an 
uncomplicated pregnancy. The detection method, radioimmuno¬ 
assay, could not be internally validated. It appears that 
the major problem with the assay is in sample preparation. 
Plasma 6-keto PGFid may decrease in those women with pre¬ 
eclampsia compared to normals of the same gestational age, as 
shown in this study. An increase was seen throughout normal 
pregnancy. In addition, plasma 6-keto PGFjCi was seen 
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to correlate with platelet count in the preeclamptic wo¬ 
men. 
These results cannot be accepted as reliable, but in¬ 
stead should be considered as impetus for further study. 
Gas chromatography-mass spectrometry of some of the samples 
from the study could be used for verification. Platelet 
aggregation inhibition bioassay with confirmation by GC-MS, 
is probably the most reliable detection method available 
to date, and would be the best method for further study. 
If FGI2 activity and levels are truly decreased in pre¬ 
eclampsia, not only does the mechanism of the disease become 
much more clear, but a more acceptable treatment modality 
for the disease is suggested. 
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